Catalyst Dossier · compiled by CeliA 🧫
Basilea Pharmaceutica (BSLN.SW)
Biotechnology · market cap $726M · as of 2026-07-21
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
None scheduled
Pipeline
18
programs
Upcoming events
0
next 90d+
Dossier
Ready
cached
Non-US-listed company. Financial statements and forensic scores here come from US SEC filings (10-K/10-Q), which foreign issuers don’t file — those sections may be blank. The catalyst calendar, pipeline, approval odds, price context and (where covered) analyst targets still apply.
Basilea Pharmaceutica (BSLN.SW) is a Swiss-listed biotechnology company with a market cap of approximately $726M and a broad pipeline spanning anti-infectives and oncology. Its lead asset isavuconazole is in Phase 3 development for Acute Myeloid Leukemia, while the pipeline also includes multiple late-stage anti-infective programs such as fosmanogepix (Phase 3, candidemia and invasive mold infections), ceftobiprole medocaril (Phase 3, skin/infectious diseases), and oncology candidates including derazantinib and BAL101553. No near-term catalysts are currently on the public calendar, and key financial metrics including cash position and runway are not disclosed in the available data.
The catalyst path
No upcoming catalysts in our calendar.
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| Isavuconazole | Phase 3 | Acute Myeloid Leukemia |
| ceftobiprole medocaril | Phase 3 | Skin Diseases, Infectious |
| derazantinib | Phase 2 | Intrahepatic Cholangiocarcinoma |
| Daptomycin | Phase 3 | Staphylococcus Aureus Bacteremia |
| Derazantinib low dose range | Phase 2 | Solid Tumor |
| alitretinoin | Phase 3 | Hand Dermatoses |
| Fosmanogepix | Phase 3 | Candidemia |
| IV standard-of-care cephalosporin | Phase 3 | Community-acquired Pneumonia (CAP) |
| linezolid plus ceftazidime | Phase 3 | Pneumonia |
| APX001 | Phase 2 | Candidemia |
| BAL101553 | Phase 2 | Neoplasms |
| Derazantinib 300 mg once daily monotherapy | Phase 2 | Urothelial Carcinoma |
| Lisavanbulin Phase 1 dose escalation portion | Phase 2 | Neoplasms |
| Ceftriaxone with or without Linezolid | Phase 3 | Pneumonia |
| Fosmanogepix IV infusion | Phase 3 | Invasive Mold Infections |
| Caspofungin | Phase 3 | Candidiasis, Invasive |
| vancomycin+aztreonam | Phase 3 | Acute Bacterial Skin and Skin Structure Infections |
| Vancomycin | Phase 3 | Skin Diseases, Infectious |
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for BSLN.SW (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 18 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.